SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
May 11, 2004
------------
Date of Report (Date of earliest event reported)
OSI PHARMACEUTICALS, INC.
-------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 0-15190 13-3159796
--------- ------- ----------
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation) File Number) Identification No.)
58 SOUTH SERVICE ROAD
MELVILLE, NY 11747
----------------------------------------
(Address of principal executive offices)
(631) 962-2000
----------------------------------------------------
(Registrant's telephone number, including area code)
N/A
----------------------------------
(Former name or former address, if
changed since last report.)
ITEM 7. EXHIBITS
EXHIBIT NO. DESCRIPTION
----------- -----------
99.1 Press release, dated May 11, 2004.
ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On May 11, 2004, OSI Pharmaceuticals, Inc. (the "Company") issued a press
release regarding its financial results for the quarter ended March 31, 2004.
The Company's press release is attached as Exhibit 99.1 to this Current Report
on Form 8-K and is incorporated by reference herein.
The information in this Current Report on Form 8-K and the Exhibit
attached hereto is being "furnished" and shall not be deemed "filed" for
purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange
Act") or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933
(the "Securities Act") or the Exchange Act, except if the Company specifically
states that the information and the Exhibit is to be considered "filed" under
the Exchange Act or incorporates it by reference into a filing under the
Securities Act or the Exchange Act.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: May 13, 2004 OSI PHARMACEUTICALS, INC.
By: /s/ Robert L. Van Nostrand
--------------------------------
Robert L. Van Nostrand
Vice President and Chief Financial
Officer (Principal Financial Officer)
EXHIBIT INDEX
EXHIBIT NO. DESCRIPTION
----------- -----------
99.1 Press release, dated May 11, 2004.